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Biochemistry and Biology of D-Dimer
D-dimer is a generic term that refers to a large number of
peptides deriving from the breakdown of a stabilized ﬁbrin
clot. At variance with the generation of ﬁbrin(ogen) degra-
dation products (FDPs), which increase in the circulation as a
result of plasmin-mediated degradation of both ﬁbrinogen
and ﬁbrin, D-dimer is produced only when both the blood
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Abstract D-dimer is the biochemical gold standard for diagnosing a variety of thrombotic
disorders, but result reporting is heterogeneous in clinical laboratories. A speciﬁc
ﬁve-item questionnaire was developed to gain a clear picture of the current standardi-
zation of D-dimer test results. The questionnaire was opened online (December 24,
2014–February 10, 2015) on the platform “Google Drive (Google Inc., Mountain View;
CA),” and widely disseminated worldwide by newsletters and alerts. A total of 409
responses were obtained during the period of data capture, the largest of which were
from Italy (136; 33%), Australia (55; 22%), Croatia (29; 7%), Serbia (26; 6%), and the
United States (21; 5%). Most respondents belonged to laboratories in general hospitals
(208; 51%), followed by laboratories in university hospitals (104; 26%), and the private
sector (94; 23%). The majority of respondents (i.e., 246; 60%) indicated the use of
ﬁbrinogen equivalent unit for expressing D-dimer results, with signiﬁcant heterogene-
ities across countries and health care settings. The highest prevalence of laboratories
indicated they were using “ng/mL” (139; 34%), followed by “mg/L” (136; 33%), and “µg/
L” (73; 18%), with signiﬁcant heterogeneity across countries but not among different
health care settings. Expectedly, the vast majority of laboratories (379; 93%) declared to
be using a ﬁxed cutoff rather than an age-adjusted threshold, with no signiﬁcant
heterogeneity across countries and health care settings. The results of this survey attest
that at least 28 different combinations of measurement units are currently used to
report D-dimer results worldwide, and this evidence underscores the urgent need for
more effective international joined efforts aimed to promote a worldwide standardiza-
tion of D-dimer results reporting.
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coagulation and ﬁbrinolytic pathways are concomitantly
activated (►Fig. 1).1 In brief, after initiation of blood coagula-
tion, ﬁbrinogen is converted to ﬁbrin by thrombin, which
enzymatically remove ﬁbrinopeptides A and B from ﬁbrino-
gen. The resulting molecule initially aggregates to form a
labile network of ﬁbrin monomers, which is then stabilized
by activated coagulation factor XIIIa (FXIIIa). In this process,
FXIIIa catalyzes the covalent linkage of the C-terminal appen-
dages of gamma-chains of adjacent ﬁbrin monomer units,
producing a stable cross-link that is effective in ensuring a
much greater degree of clot stability in injured vessels, thus
preventing excessive bleeding (►Fig. 1). The further activa-
tion of the ﬁbrinolytic pathway leads to a plasmin-mediated
degradation of the stabilized ﬁbrin network, with generation
of cross-linked (i.e., D–D) FDPs.1 It is hence clear that while
the enhanced presence in the circulation of FDPs reﬂects a
nonspeciﬁc process of both ﬁbrinogen (i.e., primary ﬁbrino-
lysis) and cross-linked ﬁbrin degradation, an increased con-
centration of D-dimer containing peptides mirrors a
contextual activation of both blood coagulation and ﬁbrino-
lysis (►Fig. 1). This explains why the measurement of
D-dimer is much more speciﬁc than FDPs for diagnosing a
thrombotic process.2
The metabolism of D-dimer after generation in blood is
prevalently renal, with minor reticuloendothelial system
clearance, displaying a half-life of approximately 6 to 8 hours
in patients with preserved kidney function.3 The relative
increase of D-dimer in plasma also depends on a large
number of variables, including the size and location of the
thrombus (i.e., patients with distal thrombosis typically have
lower D-dimer values than those with proximal thrombosis),
the time of measurement after thrombosis, and the estab-
lishment of anticoagulant therapy (anticoagulant treatment
may considerably limit clot expansion and thus reduce
D-dimer generation).4 As the results of a physiological aging
of the coagulation system,5 D-dimer values progressively
increase with age, being nearly 5- to 10-fold higher in those
> 65 years compared with childhood age.6 Increased values
are also typically observed in uncomplicated pregnancies.7
Clinical Usefulness of D-Dimer
Despite D-dimer remaining the biochemical gold standard for
diagnosing venous thromboembolism (VTE) and disseminat-
ed intravascular coagulation (DIC),8–10 several biological,
clinical, and analytical challenges emerge. First, although an
enhanced concentration of D-dimer is a reliable index of
thrombosis, rather understandably it can not be speciﬁc
enough for one thrombotic pathology.11 Accordingly, in-
creased D-dimer values are typically found in patients with
VTE,12 DIC,13 but also in those with other thrombotic dis-
orders such as cerebral or retinal vein thrombosis,14,15 acute
coronary syndrome,16 stroke,17 peripheral occlusive dis-
ease,18 acute aortic dissection,19 as well as in a large series
of conditions that may be associated with hyperactivation of
blood coagulation and ﬁbrinolysis. These typically include
trauma,20 surgery,21 severe infection or sepsis,22 cancer,23
and atrial ﬁbrillation.24
Due to the high diagnostic sensitivity (up to 100%) and
relatively low speciﬁcity of D-dimer for thrombotic disorders
such as VTE or DIC (i.e., 30–70%),3 its measurement does not
achieve a satisfactory performance for the effective diagnosis
of thrombosis, and must hence be used in combination with
prediction rules (i.e., Geneva or Well score) and diagnostic
Fig. 1 In vivo generation of FDPs and D-dimer. FDP, ﬁbrin/ﬁbrinogen degradation products.
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imaging (i.e., Doppler ultrasonography, scintigraphy,
computed tomography) to increase its positive predictive
value.8
Another important aspect is related to the still unmet
standardization of the analytical techniques used for D-dimer
measurement, which mostly entail enzymatic or latex-
enhanced turbidimetric immunoassays. As previously
explained, D-dimer is not a single molecule, but a heteroge-
neous mix of FDPs containing cross-linked D–D domains
(►Fig. 1). This explains why a universal standard has not
been successfully produced so far,5 and especially why
commercial methods, using different monoclonal antibodies
against the D–D domain, display imperfect correlations.25,26
Although speciﬁc recommendations have recently been pub-
lished,10 reporting of D-dimer results is also unfortunately
still highly heterogeneous among laboratories across the
world. Speciﬁcally, results may be reported in terms of D-
dimer unit (DDU) or ﬁbrinogen equivalent unit (FEU), and as
many as seven different units of measurement are in use (i.e.,
ng/mL, mg/L, µg/L, µg/mL, g/L, g/mL, and mg/dL). Moreover,
results can be also reported, according to a ﬁxed or an age-
adjusted cutoff (i.e., [age-adjusted cutoff, µg/L FEU] ¼ [age,
years])  10), to increase the test speciﬁcity with increasing
age.10 This problem is not without meaningful implications.
Although an external quality assessment program based on
commercially prepared lyophilized human plasma spiked
with human-derived D-dimer components showed that the
rate of results falling within the appropriate range (normal/
negative or abnormal/positive) was remarkably high (i.e., 96–
99%),27 it is considered unacceptable that the same patient
may receive different results from neighboring laboratories
using different means of reporting D-dimer values; this
would challenge the direct comparison of longitudinal data,
and may also confound busy physicians who are required to
distinguish between dozens of different ways that may be
used for expressing results.
The Survey
To the best of our knowledge, only one previous (U.S.-based)
survey (with 1,506 responders) has been published (by the
College of American Pathologists [CAP]) on the issue of
D-dimer results.28 Therefore, a speciﬁc, ﬁve-item question-
naire was developed, to gain a much broader picture of the
current standardization of D-dimer results across laboratories
worldwide. The leading aspects that were pursued included
the originating country of the laboratory, its setting within the
health care system (i.e., university hospital, general hospital,
private facility, other), the expression of results in DDU or FEU,
the unit of measurement (e.g., ng/mL, g/mL, mg/L, g/L, µg/L,
µg/mL, andothers), and theuseofﬁxedor age-adjusted cutoffs.
The online version of the questionnaire is still available at:
https://docs.google.com/forms/d/1IVMqgIsZRN_rqbv2Pdh-
PoerRB6UERXdEuCi0Czr-7m0/viewform (Accessed February 10,
2015), and will be kept open to permit ongoing assessment of
trends.
The questionnaire was designed and distributed with the
platform “Google Drive” (Google Inc. Mountain View, CA). The
survey was opened on November 24, 2014 and was dissemi-
nated by a variety of means, including newsletters and alerts
by national and international scientiﬁc societies of laboratory
medicine or hemostasis, and was also advertized in two
scientiﬁc Web sites, “Researchgate” (Available at: https://
www.researchgate.net/. Accessed: February 10, 2015) and
“The Fritsma Factor” (Available at: http://www.fritsmafac-
tor.com/. Accessed: February 10, 2015). Data collection for
this report was ﬁnalized on February 10, 2015, but as
mentioned above the survey remains open.
Results of the Survey
General Response
A ﬁnal number of 409 responses were obtained up to the time
of data analysis. The geographical distribution and the set-
tings of the responding laboratories are shown in ►Fig. 2.
Brieﬂy, the largest number of responses were obtained from
Italy (136; 33%) and Australia (55; 22%), followed by Croatia
(29; 7%), Serbia (26; 6%), and the United States (21; 5%).
As regards the setting of the laboratory within the health
care system, the majority of respondents belonged to labora-
tories in general hospitals (208; 51%), followed by laborato-
ries in university hospitals (104; 26%), and then the private
sector (94; 23%). A marginal percentage of respondents
(3; 1%) declared to be employed within other types of
laboratories.
Expression as D-Dimer Unit or Fibrinogen
Equivalent Unit
The responses to the ﬁrst speciﬁc question of the survey, that
is expression of D-dimer results as DDU or FEU, are shown
in ►Fig. 3. The majority of respondents (i.e., 246; 60%)
indicated FEU as the current unit used for expressing D-dimer
results. This data compares favorably with the CAP survey, in
which nearly 59% of the responders used FEU.28 The
frequency of DDU was found to be slightly different across
Fig. 2 Country distribution of respondents to the survey.
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four of theﬁve countrieswith the largest number of responses
in Italy and United States than in Australia and Croatia (chi-
square statistic, 16.8; p ¼ 0.001 for trend). The prevalence of
DDU usage was also found to be higher in the university and
general hospital, than in private facilities (chi-square statistic,
9.8; p ¼ 0.007 for trend) (►Fig. 3).
Units of Measurement
The responses to the second speciﬁc question of the survey, that
is the DDU of measurement, are shown in ►Fig. 4. Compared
with the CAP survey, in which 50% of the respondents used
“ng/mL,” followed by “g/mL” (28%), “mg/L” (20%), and “g/L”
(2%),28 a signiﬁcant number of replies indicating “µg/L” was
observed in our study (73; 18% compared with 0% in CAP
survey). Only two (0.5%) laboratories in our study were still
using qualitative results (i.e., positive/negative). However, aswas
the case in the CAP survey,28 the highest prevalence of laborato-
ries indicated to be using “ng/mL” (139; 34%), closely followedby
mg/L (136; 33%). Unlike the CAP survey, we did not collect any
response for “g/mL.”As regards four of theﬁve countrieswith the
largest number of responses, a much greater number of labora-
tories using “ng/mL” were found in Italy; however, “mg/L” was
largely prevailing in Australia and Croatia, whereas “µg/L” was
largely used in the United States (chi-square statistic, 109.1;
p < 0.001 for trend). No signiﬁcant differences could be
observed across the different types of facilities (chi-square
statistic, 2.8; p ¼ 0.827 for trend) (►Fig. 4).
Age-Adjusted D-Dimer Cutoffs
The responses to the third speciﬁc question of the survey, that
is, the use or not of age-adjusted D-dimer cutoffs is shown
in ►Fig. 5. Expectedly, the vast majority of laboratories (379;
93%) declared to be using a ﬁxed cutoff for D-dimer test
reporting. A direct comparison with the CAP survey is unfea-
sible, as this itemwas not present in the U.S.-based question-
naire.28 As regards four of the ﬁve countries with the largest
number of responses, the frequency of centers using age-
adjusted cutoffs were higher in Italy, intermediate in the
United States, low in Australia and zero in Croatia, but the
difference across such countries did not reach statistical
signiﬁcance (chi-square statistic, 7.3; p ¼ 0.062 for trend).
Similarly, no signiﬁcant differences could be observed across
the different types of facilities (chi-square statistic, 2.3;
p ¼ 0.314 for trend) (►Fig. 5).
Discussion
Although it is now clearly established that most problems in
the hemostasis laboratory emerge from the preanalytical
phase,29 postanalytical events related to reporting and inter-
pretation of test results are still the cause of a large number of
diagnostic errors, which can ultimately jeopardize patient
safety.30
As regards to D-dimer testing, the use of so many different
units of measurement is particularly alarming. The physi-
cians, who are not aware of the current lack of standardiza-
tion of test reporting, may be confused by receiving
nonstandardized reports from neighboring laboratories. A
paradigmatic example is the use of DDU or FEU (1 FEU ¼
2  DDU) in two facilities within the same network of
laboratories. When a patient is transferred from one facility
reporting data in DDU to another using FEU (both using an
Fig. 3 Use of DDU or FEU for D-dimer reporting among respondents to the survey. DDU, D-dimer unit; FEU, ﬁbrinogen-equivalent unit.
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identical unit of measurement, e.g., ng/mL), the expected
result in the latter laboratory would be twice as high as
that in the former (i.e., 400 ng/mL DDU ¼ 800 ng/mL FEU).
Nonetheless, the busy physicians, especially those working in
emergency departments or intensive care units, may over-
look the fact that the previous patient data might have been
reported in concentration of D-dimer, and they may hence
interpret the actual results expressed in FEU as a “pathologi-
cal” doubling of level. The use of different units of measure-
ment is perhaps less critical, wherein “µg/L” equals “ng/mL,”
whereas the values in “µg/L” are 1,000-fold higher than those
in “mg/L” or in “µg/mL,” so that they are less likely to be
confounded. Another important aspect involves the age-
related changes in blood coagulation, which favor the devel-
opment of a hypercoagulable state in the elderly,5,31 which is
ultimately reﬂected byan age-dependent increase of D-dimer
values.6 This evidence paved the way to a large number of
clinical studies aimed at deﬁning age-dependent D-dimer
cutoffs, to further increase the diagnostic speciﬁcity of this
biomarker in the elderly.6 Although speciﬁc recommenda-
tions to use age-adjusted cutoffs were also published,10,32 no
precise information before this survey was available as to
whether these suggestions have been followed.
Major efforts are currently being placed in harmonizing
D-dimer measurements with different methods.33,34 Inter-
estingly, the Fibrinogen and Factor XIII Subcommittee of the
Scientiﬁc Standardization Committee of the International
Society on Thrombosis and Hemostasis (ISTH) has published
recommendations about the nomenclature of ﬁbrinogen and
ﬁbrin,35 but D-dimer was not included.
The ﬁrst conclusion that can be drawn from the results of
this large international survey is that D-dimer is probably the
most paradigmatic example of poor standardization of labo-
ratory test reporting in the broad ﬁeld of laboratory diag-
nostics. It is noteworthy that 28 different combinations of
units of measurement were reported overall by survey
respondents (2 between DDU or FUE  7 measurement units
 2 between ﬁxed or age-adjusted cutoff). This scenario is
even worse than that previously estimated from the CAP
survey. It is also noteworthy that the term D-dimer does not
even identify a homogenous analyte, but comprises amixture
of degradation products of stabilized ﬁbrin with molecular
weights potentially ranging from 190 to > 10,000 kDa
(►Fig. 1).34 This obviously makes the expression in a hypo-
thetical “mol/L” standard unit virtually unfeasible. The unit of
measurement which is probably more in line with the
International System (IS) is “µg/L,” which is also essentially
the same as “ng/mL.” Interestingly, these account for the vast
majority of responses collected in our survey (18% µg/L and
34% ng/mL, totaling 52% of overall responses). As regards DDU
and FEU, the combination of the latter format with “µg/L”
would generate a cutoff of approximately 500 µg/L FEU for
patients aged 50 years and younger, which is the most
accurate diagnostic threshold identiﬁed in a large systematic
Fig. 4 Use of different measure units for D-dimer reporting among respondents to the survey.
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review and meta-analysis including 13 cohort studies and
12,497 patients.32 As regards age-adjusted cutoffs, several
lines of evidence now attest that the use of this approach
considerably enhances the positive predictive value of this
biomarker, with negligible impact on the negative predictive
value.32 It seems therefore reasonable to suggest that the use
of age-adjusted cutoffs should be further promoted for
improving the clinical usefulness of D-dimer testing in elderly
patients with nonhigh clinical probability.
Understandably, the authors of the current report are not
in a position to provide any ofﬁcial recommendations toward
the use of one unit or another. Indeed, differences in reporting
approach were also identiﬁed among the authors of this
report. However, the results of the international survey
clearly attest that large supranational societies in charge of
harmonizing practices within hemostasis laboratories, such
as the ISTH or the International Federation of Clinical Chem-
istry and Laboratory Medicine, should take a lead role to
pursue the challenging enterprise of standardizing D-dimer
results reporting, along with harmonizing data among differ-
ent manufacturer products.
It is, however, recognized that the introduction of a
widespread standardization of D-dimer reporting also carries
many challenges and some mindful drawbacks. First, the
adoption of common means of test reporting would go
against individual manufacturers’ recommendations unless
manufacturers agreed on a common approach. This has many
additional signiﬁcant implications, since following manufac-
turer’s recommendations are inherently requirements of
continued laboratory practice including accreditation and
regulatory conditions.36 Second, it will also introduce a
further source of variability when attempting to translate
cutoffs previously established in large and reliable clinical
studies and then adapted to daily practice. Moreover, any
change in test practice may lead to confusion of laboratory
staff and clinicians using the test, at least in the initial phase of
transition toward a new standardized means of expressing
results. Therefore, an appropriate policy of information and
education should be locally established, to prevent such
changes in the units of measurement becoming an additional
and unwanted source of confusion for clinicians.
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